Abstract:In pediatric age and particularly in newborn infants the drug efficacy and safety are influenced by the growth and development on drug Absorption, Distribution, Metabolism and Excretion (ADME). Thanks to the fast development of pharmacogenomics and pharmacogenetics, the drug therapy promises to be adapted to the genetic profile of the individual, reducing considerably the side effects of drugs and increasing their efficacy. Interindividual variability in drug response is well known in both adults and children. Such a variability is multifactorial considering both intrinsic and extrinsic factors. Drug distribution in the neonate is influenced by a variety of age-dependent factors as a total body water content and distribution variations, role of drug transporters, blood/tissue protein binding, blood and tissue pH and perfusion. The development of enzymes involved in human metabolism were classified in 3 categories: 1) those expressed during the whole or part of the fetal period, but silenced or expressed at low levels within 1-2 years after birth; 2) those expressed at relatively constant levels throughout fetal development, but increased to some extent postnatally; and 3) those whose onset of expression can occur in the third trimester, but substantial increase is noted in the first 1-2 years after birth. Besides this intrinsic aspects influencing pharmacokinetics during the neonatal period there are other important events such as inborn or acquired diseases, environment and finally pharmacogenetics and pharmacogenomics. Thousands of deaths every years are caused by fatal drug reactions; among the potential causes there are not only the severity of the disease being treated, drug interactions, nutritional status, renal and liver functions, but also the inherited differences in drug metabolism and genetic polymorphism. Adverse drug reactions (ADRs) among pediatric patients have been shown to be three times more frequent than in adults. On August 2010 The National Institute of Child Health and Human Development (NICHD) addressed patient safety issues in the NICU, recognizing that to understand and prevent adverse events, systematic research and education in safety issues needed. From all these concepts in terms of ADME, pharmacogenetics (relative to a single gene) and pharmacogenomics (relative to many genes) it is becoming more evident the perspective of the new concept of individualized medicine. The goal of this should be to identify which group of patients responds positively, which patients are nonresponders and who experiences adverse reaction for the same drug and dose. The interindividual variability in response to any drug is mostly dependent on DNA sequence variations across the human genome, the haplotype map (HAPMAP). At present there is still a big distance beween the knowledge in genetic and the practical application to model the drug profile to the genetic/genomic profile of the single patient. In the neonatal period the effects of growth in the pharmacodynamic, processes can help optimizing the dosage of neonatal frequently used medicines, thereby, minimizing their toxicity and increasing their efficacy. It should be useful to create accurate dosage adjustments according to the week of development.

Developmental pharmacogenetics of CYP2C19 in neonates and young infants: omeprazole as a probe drug.

Evaluation of the Relationship Between Polymorphisms in CYP2C19 and the Single‐dose Pharmacokinetics of Omeprazole in Healthy Chinese Volunteers: A Multicenter Study

Population pharmacokinetics of cisapride in neonates

Improving CYP2C19 phenotyping using stereoselective omeprazole and 5‐hydroxy‐omeprazole metabolic ratios

Ontogeny and drug metabolism in newborns

Study of the effect of CYP2C19 polymorphisms on omeprazole pharmacokinetics by utilizing validated LC-MS/MS and Real Time-PCR methods

Developmental Pharmacokinetics in Pediatric Populations.

Developmental Population Pharmacokinetics and Dosing Optimization of Cefepime in Neonates and Young Infants.

Effects of CYP2C19 polymorphism on pharmacokinetic profile and comparative bioavailability of omeprazole

Analyses of the Phenotype Polymorphism of Cytochrome CYP2C19in Chinese Han

Influence of CYP2C19 on the Relationship Between Pharmacokinetics and Intragastric Ph of Omeprazole Administered by Successive Intravenous Infusions in Chinese Healthy Volunteers

Inducibility of CYP1A2 by Omeprazole in Vivo Related to the Genetic Polymorphism of CYP1A2.

Expression of intestinal drug transporter proteins and metabolic enzymes in neonatal and pediatric patients

Prediction of Pediatric Pharmacokinetics for CYP3A4 Metabolized Drugs: Comparison of the Performance of Two Hepatic Ontogeny Within a Physiologically Based Pharmacokinetic Model

First Dose in Neonates: Pharmacokinetic Bridging Study from Juvenile Mice to Neonates for Drugs Metabolized by CYP3A.

Pharmacodynamic Effects and Kinetic Disposition of Rabeprazole in Relation to CYP2C19 Genotype in Healthy Chinese Subjects1

Phenoconversion Due to Drug-Drug Interactions in CYP2C19 Genotyped Healthy Volunteers

Clopidogrel Inhibits CYP2C19‐Dependent Hydroxylation of Omeprazole Related to CYP2C19 Genetic Polymorphisms

Developmental Expression of Drug Transporters and Conjugating Enzymes Involved in Enterohepatic Recycling: Implication for Pediatric Drug Dosing

Influence of novel CYP2C‐haplotype on proton pump inhibitor pharmacokinetics in children

Evaluation of the Effects of 20 Nonsynonymous Single Nucleotide Polymorphisms of CYP2C19 Ons-Mephenytoin 4′-Hydroxylation and Omeprazole 5′-Hydroxylation